-
Traws Pharma, Inc. NasdaqCM:TRAW Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Location: 12 Penns Trail, Newtown, PA, 18940, United States | Website: https://www.trawspharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-15.76M
Cash
21.34M
Avg Qtr Burn
-7.448M
Short % of Float
2.00%
Insider Ownership
19.68%
Institutional Own.
32.57%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rigosertib + Pembrolizumab Details Melanoma, Skin cancer, Cancer | Phase 2 Data readout | |
Rigosertib Details Cutaneous squamous cell carcinoma, Cancer, Solid tumor/s | Phase 2 Update | |
TRX100 (tivoxavir marboxil) Details Influenza, Viral infection | Phase 2 Initiation | |
Ratutrelvir (TRX01) Details COVID-19 | Phase 2a Initiation | |
Rigosertib + Nivolumab Details Cancer, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
Narazaciclib + letrozole Details Cancer, Solid tumor/s, Endometrial cancer | Phase 1/2 Data readout | |
Narazaciclib (ON 123300) Details Solid tumor/s, Cancer, Breast cancer, ER+/HER2- breast cancer, Metastatic breast cancer | Phase 1/2 Update | |
Rigosertib Details Myelodysplastic syndrome | Failed Discontinued |